Opus Genetics IRD Share-Based Payment - Unrecognized Cost of Nonvested Awards
Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's share-based payment - unrecognized cost of nonvested awards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's share-based payment - unrecognized cost of nonvested awards?
- Opus Genetics (IRD) reported share-based payment - unrecognized cost of nonvested awards of $1.31 in Q1 2026.
- How has Opus Genetics's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
- Opus Genetics's share-based payment - unrecognized cost of nonvested awards decreased by 31.4% year-over-year, from $1.91 to $1.31.
- What is the long-term trend for Opus Genetics's share-based payment - unrecognized cost of nonvested awards?
- Over 2 years (2023 to 2025), Opus Genetics's share-based payment - unrecognized cost of nonvested awards has grown at a -100.0% compound annual growth rate (CAGR), from $6,400,000.00 to $1.31.
- What does share-based payment - unrecognized cost of nonvested awards mean?
- This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.